ClinicalTrials.gg
CompletedNCT01774344RESORCEUpdated Aug 20, 2020Results posted

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Carcinoma, Hepatocellular, sponsored by Bayer. Completed at 147 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
573
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.

Enrollment
2nd of 22
573 · median 33
Started
2013
the only one that year
Phase 3
2 of 22
none open now
Registered
2nd of 22
by date
Lead sponsor
5 of 22
Bayer

Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 2nd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing regorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • Regorafenib
  • BAY73-4506
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmation of HCC (hepatocellular carcinoma) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases criteria in patients with a confirmed diagnosis of cirrhosis
  • Barcelona Clinic Liver Cancer stage Category B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation, chemoembolization or systemic sorafenib.
  • Failure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within 10 weeks after the last treatment with sorafenib.
  • Tolerability of prior treatment with sorafenib defined as not less than 20 days at a minimum daily dose of 400 mg QD within the last 28 days prior to withdrawal.
  • Liver function status Class A. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period.

Local or loco-regional therapy of intrahepatic tumor lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed >/=4 weeks before first dose of study medication. Note: patients who received sole intrahepatic intraarterial chemotherapy, without lipiodol or embolizing agents are not eligible.

  • Performance Status of 0 or 1.
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory tests conducted within 7 days before randomization.
  • >/= 30 ml/min/1.73 m\^2 according to the Modification of diet in renal disease study equation.
  • At least one uni-dimensional by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to (RECIST version 1.1), and modified RECIST for HCC. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
  • of at least 3 months.
  • Women of and men must agree to use adequate .

Exclusion criteria

Exclusion Criteria :

  • Sorafenib treatment within 2 weeks of randomization.
  • Prior systemic treatment for HCC, except sorafenib.
  • Permanent discontinuation of prior sorafenib therapy due to sorafenib related toxicity.
  • Known history or symptomatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease).
  • Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
  • Uncontrolled ascites (defined as not easily controlled with diuretic or paracentesis treatment).
  • Ongoing infection > Grade 2 according to (National Cancer Institute - Common Terminology Criteria for Adverse Events) v. 4.0. is allowed if no active replication is present. is allowed if no antiviral treatment is required.
  • bleeding NCI-CTCAE version 4.0 Grade 3 or higher within 30 days before randomization.
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.
  • Patients unable to swallow oral medications.
  • Interstitial lung disease with ongoing signs and symptoms at the time of screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
573 participants (actual)

Study arms

  • Experimental
    Regorafenib

    160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)

    Drug: Regorafenib (Stivarga, BAY73-4506)

  • Placebo comparator
    Placebo

    4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.

    Time frame: From randomization (Day 1) of the first subject until 419 days later

Secondary outcomes

  1. Time to Progression (TTP)

    TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.

    Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)

  2. Progression Free Survival (PFS)

    Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.

    Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)

  3. Objective Tumor Response Rate (ORR)

    Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis.

    Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)

  4. Disease Control Rate (DCR)

    Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating.

    Time frame: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)

Other outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause

    Time frame: From randomization (Day 1) of the first subject to end of follow upto 1710 days

07

Results

Posted Jun 5, 2017
Limitations and caveats
Decimal places were automatically truncated if last decimal equals zero.

Participant flow

The study was conducted between 14 May 2013 (first subject first visit), 29 February 2016 (primary completion date) and 05-July-2019 (Last Patient Last Visit =End of study).

Participant flow — Overall Study
MilestonePlaceboRegorafenib 160 mg (BAY73-4506)
Started194379
Treated193374
Entered survival fu145291
Completed132258
Not completed62121
Withdrew: Withdrawal by subject310
Withdrew: Protocol violation01
Withdrew: Lost to follow-up410
Withdrew: End of survival follow-up not available22
Withdrew: Data collection finished414
Withdrew: Other01
Withdrew: Did not enter survival follow up4983

Outcome measures

PrimaryOverall Survival (OS)

Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.

Time frame:
From randomization (Day 1) of the first subject until 419 days later
Reported as:
Median · days
Overall Survival (OS)
daysPlaceboRegorafenib 160 mg (BAY73-4506)
Overall Survival (OS)237 ± 192323 ± 276
Statistical analysis
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = = 0.000017 · Hazard ratio (hr): 0.624 · 95% CI 0.498 to 0.782
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = = 0.000149 · Hazard ratio (hr): 0.660 · 95% CI 0.527 to 0.828
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = = 0.000107 · Hazard ratio (hr): 0.674 · 95% CI 0.546 to 0.831
SecondaryTime to Progression (TTP)

TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.

Time frame:
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Reported as:
Median · days
Time to Progression (TTP)
daysPlaceboRegorafenib 160 mg (BAY73-4506)
mRECIST45 ± 4497 ± 87
RECIST 1.145 ± 44119 ± 87
Statistical analysis
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.439 · 95% CI 0.355 to 0.542
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.471 · 95% CI 0.388 to 0.572
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.412 · 95% CI 0.334 to 0.509
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.444 · 95% CI 0.365 to 0.539
SecondaryProgression Free Survival (PFS)

Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.

Time frame:
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)
Reported as:
Median · days
Progression Free Survival (PFS)
daysPlaceboRegorafenib 160 mg (BAY73-4506)
mRECIST45 ± 4495 ± 86
RECIST 1.145 ± 44102 ± 87
Statistical analysis
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.453 · 95% CI 0.369 to 0.555
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.480 · 95% CI 0.397 to 0.580
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.425 · 95% CI 0.347 to 0.522
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Log Rank · p = < 0.000001 · Hazard ratio (hr): 0.454 · 95% CI 0.376 to 0.548
SecondaryObjective Tumor Response Rate (ORR)

Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis.

Time frame:
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Reported as:
Number · percentage of subjects
Objective Tumor Response Rate (ORR)
percentage of subjectsPlaceboRegorafenib 160 mg (BAY73-4506)
mRECIST4.110.8
RECIST 1.12.66.6
Statistical analysis
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Cochran-Mantel-Haenszel · p = = 0.003650 · Difference: -6.88 · 95% CI -11.13 to -2.63
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Cochran-Mantel-Haenszel · p = = 0.019991 · Difference: -4.15 · 95% CI -7.55 to -0.75
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating.

Time frame:
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Reported as:
Number · percentage of subjects
Disease Control Rate (DCR)
percentage of subjectsPlaceboRegorafenib 160 mg (BAY73-4506)
mRECIST36.165.2
RECIST 1.134.565.7
Statistical analysis
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Cochran-Mantel-Haenszel · p = < 0.000001 · Difference: -29.31 · 95% CI -37.52 to -21.11
  • Placebo vs Regorafenib 160 mg (BAY73-4506) · Cochran-Mantel-Haenszel · p = < 0.000001 · Difference: -31.39 · 95% CI -39.57 to -23.22
Other pre-specifiedOverall Survival (OS)

Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause

Time frame:
From randomization (Day 1) of the first subject to end of follow upto 1710 days
Reported as:
Median · days
Overall Survival (OS)
daysPlaceboRegorafenib 160 mg (BAY73-4506)
Overall Survival (OS)241 ± 196326 ± 278

Adverse events

Collected over Adverse event data were collected after start of study drug administration until 30 days after end of study treatment over a period of approximately three years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo176/193 (91.2%)92/193 (47.7%)162/193 (83.9%)
Regorafenib (Stivarga, BAY73-4506)324/374 (86.6%)194/374 (51.9%)366/374 (97.9%)
Most frequent serious events
Showing 10 of 177
Most frequent serious events
EventPlaceboRegorafenib (Stivarga, BAY73-4506)
General physical health deteriorationGeneral disorders25/19347/374
Hepatic failureHepatobiliary disorders9/1939/374
AscitesGastrointestinal disorders6/19310/374
Hepatic encephalopathyNervous system disorders3/1939/374
PneumoniaInfections and infestations1/1938/374
Abdominal painGastrointestinal disorders4/1932/374
Oesophageal varices haemorrhageGastrointestinal disorders1/1936/374
Upper gastrointestinal haemorrhageGastrointestinal disorders3/1936/374
PyrexiaGeneral disorders1/1936/374
Back painMusculoskeletal and connective tissue disorders2/1936/374
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlaceboRegorafenib (Stivarga, BAY73-4506)
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders15/193194/374
DiarrhoeaGastrointestinal disorders31/193163/374
Decreased appetiteMetabolism and nutrition disorders29/193122/374
HypertensionVascular disorders14/193119/374
FatigueGeneral disorders50/193110/374
Aspartate aminotransferase increasedInvestigations40/19399/374
Blood bilirubin increasedInvestigations30/19394/374
Abdominal painGastrointestinal disorders29/19385/374
PyrexiaGeneral disorders13/19379/374
NauseaGastrointestinal disorders26/19372/374

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRegorafenib 160 mg (BAY73-4506)Total
Mean61.1 ± 11.661.8 ± 12.461.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
Female234669
Male171333504
Eastern cooperative oncology group (ECOG) Performance Status (PS) (data collection system-RAVE)
Eastern cooperative oncology group (ECOG) Performance Status (PS) (data collection system-RAVE)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
ECOG PS 0130247377
ECOG PS 164132196
ECOG PS: Interactive voice response system (IVRS)
ECOG PS: Interactive voice response system (IVRS)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
ECOG PS 0129251380
ECOG PS 165128193
Alpha-fetoprotein (AFP) (RAVE)
Alpha-fetoprotein (AFP) (RAVE)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
less than (<) 400 nanogram per milliliter (ng/mL)107217324
greater than or equal to (>=) 400 ng/mL87162249
Alpha-fetoprotein (AFP) (IVRS)
Alpha-fetoprotein (AFP) (IVRS)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
< 400 ng/mL105212317
>= 400 ng/mL89167256
Macrovascular invasion (RAVE)
Macrovascular invasion (RAVE)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
Absence140269409
Presence54110164
Macrovascular invasion (IVRS)
Macrovascular invasion (IVRS)(Participants)PlaceboRegorafenib 160 mg (BAY73-4506)Total
Absence135262397
Presence59117176

3 further baseline measures are reported on the registry.

08

Study locations

147 sites
  • Los Angeles, California 90048, United States
  • Los Angeles, California 90095, United States
  • Orange, California 92868-3201, United States
  • Aurora, Colorado 80045, United States
  • Washington, District of Columbia 20007-2197, United States
  • Gainesville, Florida 32610-0286, United States
  • Tampa, Florida 33606, United States
  • Chicago, Illinois 60637, United States
  • Louisville, Kentucky 40202, United States
  • Worcester, Massachusetts 01655, United States
  • Minneapolis, Minnesota 55455, United States
  • Saint Louis, Missouri 63110, United States
  • New York, New York 10029, United States
  • Rochester, New York 14642, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Richmond, Virginia 23249, United States
  • Seattle, Washington 98101, United States
  • Pilar, Buenos Aires B1629ODT, Argentina
  • Camperdown, New South Wales 2050, Australia
  • Liverpool, New South Wales 2170, Australia
  • Herston, Queensland 4029, Australia
  • Clayton, Victoria 3168, Australia
  • Box Hill, 3128, Australia
  • Linz, Oberösterreich 4020, Austria
  • Graz, Steiermark 8036, Austria
  • Wien, 1090, Austria
  • Bruxelles - Brussel, 1090, Belgium
  • La Louviere, 7100, Belgium
  • Salvador, Bahia 41950-610, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Hefei, Anhui 230022, China
  • Fuzhou, Fujian 350025, China
  • Guangzhou, Guangdong 510060, China
  • Guangzhou, Guangdong 510080, China
  • Guangzhou, Guangdong 510515, China
  • Nanning, Guangxi 530021, China
  • Harbin, Heilongjiang 150081, China
  • Wuhan, Hubei 430030, China
  • Changsha, Hunan 410013, China
  • Nanjing, Jiangsu 210002, China
  • Suzhou, Jiangsu 215006, China
  • Dalian, Liaoning 116011, China
  • Xi'an, Shaanxi 710032, China
  • Xi'an, Shaanxi 710038, China
  • Xi'an, Shaanxi 710061, China
  • Chengdu, Sichuan 610041, China
  • Beijing, 100039, China
  • Beijing, 100069, China
  • Beijing, 100071, China
  • Beijing, 100142, China
  • Chongqing, 400038, China
  • Shanghai, 200001, China
  • Shanghai, 200032, China
  • Shanghai, 201805, China
  • Tianjin, 300060, China
  • Hradec Kralove, 500 05, Czechia
  • Olomouc, 775 20, Czechia
  • Praha 2, 128 08, Czechia
  • Angers, 49100, France
  • Caen, F-14033, France
  • Clichy, 92110, France
  • Creteil, 94010, France
  • Dijon, 21000, France
  • La Tronche, 38700, France
  • Lille, 59037, France
  • Lyon, 69004, France
  • Marseille, 13005, France
  • Montpellier Cedex, 34295, France
  • Nice Cedex 3, 06202, France
  • Paris, 75020, France
  • Paris, 75651, France
  • Perpignan, 66000, France
  • Reims Cedex, 51092, France
  • Rennes Cedex, 35062, France
  • Toulouse, 31059, France
  • Vandoeuvre les Nancy, 54500, France
  • Villejuif Cedex, 94805, France
  • Heidelberg, Baden-Württemberg 69120, Germany
  • München, Bayern 81377, Germany
  • Frankfurt, Hessen 60590, Germany
  • Hannover, Niedersachsen 30625, Germany
  • Aachen, Nordrhein-Westfalen 52074, Germany
  • Essen, Nordrhein-Westfalen 45136, Germany
  • Köln, Nordrhein-Westfalen 50937, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Magdeburg, Sachsen-Anhalt 39120, Germany
  • Berlin, 13353, Germany
  • Hamburg, 20246, Germany
  • Budapest, 1097, Hungary
  • Debrecen, 4032, Hungary
  • Kaposvar, 7400, Hungary
  • Napoli, Campania 80131, Italy
  • Bologna, Emilia-Romagna 40138, Italy
  • Modena, Emilia-Romagna 41124, Italy
  • Roma, Lazio 00168, Italy
  • Genova, Liguria 16132, Italy
  • Bergamo, Lombardia 24127, Italy
  • Milano, Lombardia 20089, Italy
  • Milano, Lombardia 20122, Italy
  • Novara, Piemonte 28100, Italy

Showing the first 100 of 147 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26. PubMed 29704513 ↗
  • Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum In: Lancet. 2017 Jan 7;389(10064):36. doi: 10.1016/S0140-6736(16)32615-0. PubMed 27932229 ↗
  • Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, Bruix J. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6. PubMed 30738047 ↗

Individual participant data

Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Feb 2016, 33 months.

Results were first posted in Jun 2017, 1 year 3 months after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2013
First posted
Jan 24, 2013
StartActual
May 14, 2013
Primary completionActual
Feb 29, 2016
CompletionActual
Jul 5, 2019
Results first posted
Jun 5, 2017
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01774344
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 24, 2013
Start date
May 14, 2013
Primary completion
Feb 29, 2016
Completion
Jul 5, 2019
Results posted
Jun 5, 2017
Last update
Aug 20, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion